630 related articles for article (PubMed ID: 32722796)
21. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
Kang HJ; Chun SM; Kim KR; Sohn I; Sung CO
PLoS One; 2013; 8(8):e72609. PubMed ID: 23967324
[TBL] [Abstract][Full Text] [Related]
23. The interplay between mutant p53 and the mevalonate pathway.
Parrales A; Thoenen E; Iwakuma T
Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
[TBL] [Abstract][Full Text] [Related]
24. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
Front Oncol; 2021; 11():642603. PubMed ID: 34178628
[TBL] [Abstract][Full Text] [Related]
25. Mutant p53 in cancer therapy-the barrier or the path.
Zhou X; Hao Q; Lu H
J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
[TBL] [Abstract][Full Text] [Related]
26. Regulation of p53 and Cancer Signaling by Heat Shock Protein 40/J-Domain Protein Family Members.
Kaida A; Iwakuma T
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948322
[TBL] [Abstract][Full Text] [Related]
27. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
28. Regulators of Oncogenic Mutant TP53 Gain of Function.
Yamamoto S; Iwakuma T
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30577483
[TBL] [Abstract][Full Text] [Related]
29. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response.
Zhao M; Wang T; Gleber-Netto FO; Chen Z; McGrail DJ; Gomez JA; Ju W; Gadhikar MA; Ma W; Shen L; Wang Q; Tang X; Pathak S; Raso MG; Burks JK; Lin SY; Wang J; Multani AS; Pickering CR; Chen J; Myers JN; Zhou G
Nat Commun; 2024 Jan; 15(1):180. PubMed ID: 38167338
[TBL] [Abstract][Full Text] [Related]
30. Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
Ubertini V; Norelli G; D'Arcangelo D; Gurtner A; Cesareo E; Baldari S; Gentileschi MP; Piaggio G; Nisticò P; Soddu S; Facchiano A; Bossi G
Oncogene; 2015 May; 34(19):2493-504. PubMed ID: 24998848
[TBL] [Abstract][Full Text] [Related]
31. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
32. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.
Alvarado-Ortiz E; de la Cruz-López KG; Becerril-Rico J; Sarabia-Sánchez MA; Ortiz-Sánchez E; García-Carrancá A
Front Cell Dev Biol; 2020; 8():607670. PubMed ID: 33644030
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy.
He C; Li L; Guan X; Xiong L; Miao X
Chemotherapy; 2017; 62(1):43-53. PubMed ID: 27322648
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.
Kamath D; Iwakuma T; Bossmann SH
Nanomedicine; 2024 Feb; 56():102732. PubMed ID: 38199451
[TBL] [Abstract][Full Text] [Related]
35. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
[TBL] [Abstract][Full Text] [Related]
36. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
Jethwa A; Słabicki M; Hüllein J; Jentzsch M; Dalal V; Rabe S; Wagner L; Walther T; Klapper W; ; Bohnenberger H; Rettel M; Lu J; Smits AH; Stein F; Savitski MM; Huber W; Aylon Y; Oren M; Zenz T
Blood; 2018 Jun; 131(25):2789-2802. PubMed ID: 29653964
[TBL] [Abstract][Full Text] [Related]
37. Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials.
Nishikawa S; Iwakuma T
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672377
[TBL] [Abstract][Full Text] [Related]
38. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
39. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
40. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]